Filter

All NewsProductsTechnology

NuProbe Technology Enables Low-Frequency DNA Variant Detection using Low-depth Sequencing

May 3, 2021
Research published in Nature Biomedical Engineering demonstrates NuProbe's technology can enable detecting single nucleotide variants (SNVs) in DNA with a…
All NewsProducts

NuProbe Launches Liquid Biopsy Pan-Cancer NGS Panel

February 22, 2021
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations…
All NewsStrategic Collaborations

NuProbe Closes $42M Fundraising

January 11, 2021
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand…
All NewsProducts

NuProbe to Offer Augury™ Custom Liquid Biopsy NGS Panels

November 16, 2020
NuProbe launches the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™…
All NewsStrategic Collaborations

NuProbe and Weigao Group Form Strategic Collaboration to Develop Liquid Biopsy Panel

June 22, 2020
NuProbe and Weigao Group will apply NuProbe's proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel…
All NewsProducts

NuProbe Licensed Two Technologies from Rice University, Launched Nanopore AML multi-gene panel

June 2, 2020
The first, Non-Extensible Oligonucleotides (NEO), will allow NuProbe to provide much more rapid development of customized NGS panels, with turnaround…
All NewsStrategic Collaborations

NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels

April 22, 2020
Two additional world-renowned oncologists will join NuProbe’s clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD…
All NewsStrategic Collaborations

NuProbe Announces Strategic Collaboration with QIAGEN, Completes Multiple CE IVD Product Registrations

March 16, 2020
NuProbe and QIAGEN will collaborate to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy. NuProbe and QIAGEN…
All NewsStrategic Collaborations

NuProbe Announces Licensing Deal with Oxford Nanopore

February 22, 2020
Oxford Nanopore has licensed NuProbe's Blocker Displacement Amplification technology globally for undisclosed consideration. The technology combination offers the potential to…
All NewsStrategic Collaborations

NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO, and Established Collaboration with Illumina

January 6, 2020
NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) announced the successful completion of their recent merger and integration. The…